alanine has been researched along with Diabetic Nephropathies in 15 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Renal fibrosis biomarkers correlated significantly with the alanine production." | 3.96 | Hyperpolarized [1- ( Bertelsen, LB; Genovese, F; Karsdal, MA; Laustsen, C; Mariager, CØ; Mølmer, M; Nielsen, PM; Nørregaard, R; Sparding, N, 2020) |
| "Insulin resistance plays a part in diabetic nephropathy (DN)." | 2.48 | Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. ( Chen, H; Chen, J; Hu, H; Mohan, V; Tang, Y; Venkatesan, R; Wang, J; Zhang, H; Zhu, S, 2012) |
| "Overt diabetic nephropathy (n = 619) was defined as having an albumin excretion rate (AER) >200 microg/min or renal replacement therapy; incipient diabetic nephropathy was defined as having an AER of 20-200 microg/min (n = 336)." | 1.34 | A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. ( Brismar, K; Dahlquist, G; Forsblom, C; Groop, PH; Marklund, SL; Möllsten, A; Parkkonen, M; Svensson, M; Wessman, M, 2007) |
| "The odds ratio of having diabetic nephropathy for Ala carriers was 0." | 1.32 | The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. ( Canani, LH; Caramori, ML; Costa, LA; Gross, JL, 2003) |
| "A total of 445 patients with type 2 diabetes who were enrolled in the Berlin Diabetes Mellitus Study and in whom we determined albuminuria and the presence of ESRF and retinopathy were genotyped for the PPAR-gamma2 Pro12Ala polymorphism." | 1.31 | Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. ( Brand, E; Herrmann, SM; Ringel, J; Staessen, JA; Wang, JG, 2002) |
| "Diabetic nephropathy is the most frequent cause of end-stage renal failure." | 1.31 | [Association of the renin-angiotensin system gene polymorphism with nephropathy in type II diabetes]. ( Buraczyńska, M; Ksiazek, A; Ksiazek, P; Nowicka, T; Spasiewicz, D; Łopatyński, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, M | 1 |
| Hu, W | 1 |
| Feng, Y | 1 |
| Tong, Y | 1 |
| Wang, X | 1 |
| Tan, B | 1 |
| Xu, H | 1 |
| Liu, J | 1 |
| Nielsen, PM | 1 |
| Mariager, CØ | 1 |
| Mølmer, M | 1 |
| Sparding, N | 1 |
| Genovese, F | 1 |
| Karsdal, MA | 1 |
| Nørregaard, R | 2 |
| Bertelsen, LB | 1 |
| Laustsen, C | 2 |
| Cassis, P | 1 |
| Locatelli, M | 1 |
| Corna, D | 1 |
| Villa, S | 1 |
| Rottoli, D | 1 |
| Cerullo, D | 1 |
| Abbate, M | 1 |
| Remuzzi, G | 2 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Rurali, E | 1 |
| Noris, M | 1 |
| Chianca, A | 1 |
| Donadelli, R | 1 |
| Banterla, F | 1 |
| Galbusera, M | 1 |
| Gherardi, G | 1 |
| Gastoldi, S | 1 |
| Parvanova, A | 1 |
| Iliev, I | 1 |
| Bossi, A | 1 |
| Haefliger, C | 1 |
| Trevisan, R | 1 |
| Ruggenenti, P | 1 |
| Lycke, S | 1 |
| Palm, F | 1 |
| Østergaard, JA | 1 |
| Bibby, BM | 1 |
| Flyvbjerg, A | 1 |
| Pedersen, M | 1 |
| Ardenkjaer-Larsen, JH | 1 |
| Azab, MM | 1 |
| Abdel-Azeez, HA | 1 |
| Zanaty, MF | 1 |
| El Alawi, SM | 1 |
| Liu, L | 1 |
| Zheng, T | 1 |
| Wang, N | 1 |
| Wang, F | 1 |
| Li, M | 1 |
| Jiang, J | 1 |
| Zhao, R | 1 |
| Li, L | 1 |
| Zhao, W | 1 |
| Zhu, Q | 1 |
| Jia, W | 1 |
| Zhang, H | 1 |
| Zhu, S | 1 |
| Chen, J | 1 |
| Tang, Y | 1 |
| Hu, H | 1 |
| Mohan, V | 1 |
| Venkatesan, R | 1 |
| Wang, J | 1 |
| Chen, H | 1 |
| Herrmann, SM | 1 |
| Ringel, J | 1 |
| Wang, JG | 1 |
| Staessen, JA | 1 |
| Brand, E | 1 |
| Buraczyńska, M | 1 |
| Ksiazek, P | 1 |
| Łopatyński, J | 1 |
| Spasiewicz, D | 1 |
| Nowicka, T | 1 |
| Ksiazek, A | 1 |
| Caramori, ML | 1 |
| Canani, LH | 1 |
| Costa, LA | 1 |
| Gross, JL | 1 |
| Möllsten, A | 1 |
| Marklund, SL | 1 |
| Wessman, M | 1 |
| Svensson, M | 1 |
| Forsblom, C | 1 |
| Parkkonen, M | 1 |
| Brismar, K | 1 |
| Groop, PH | 1 |
| Dahlquist, G | 1 |
| Al-Kateb, H | 1 |
| Boright, AP | 1 |
| Mirea, L | 1 |
| Xie, X | 1 |
| Sutradhar, R | 1 |
| Mowjoodi, A | 1 |
| Bharaj, B | 1 |
| Liu, M | 1 |
| Bucksa, JM | 1 |
| Arends, VL | 1 |
| Steffes, MW | 1 |
| Cleary, PA | 1 |
| Sun, W | 1 |
| Lachin, JM | 1 |
| Thorner, PS | 1 |
| Ho, M | 1 |
| McKnight, AJ | 1 |
| Maxwell, AP | 1 |
| Savage, DA | 1 |
| Kidd, KK | 1 |
| Kidd, JR | 1 |
| Speed, WC | 1 |
| Orchard, TJ | 1 |
| Miller, RG | 1 |
| Sun, L | 1 |
| Bull, SB | 1 |
| Paterson, AD | 1 |
| Terentyeva, EA | 1 |
| Hayakawa, K | 1 |
| Tanae, A | 1 |
| Katsumata, N | 1 |
| Tanaka, T | 1 |
| Hibi, I | 1 |
| Garber, AJ | 1 |
| Bier, DM | 1 |
| Cryer, PE | 1 |
| Pagliara, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)[NCT00235014] | Phase 4 | 1,204 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alanine and Diabetic Nephropathies
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies.
Topics: Alanine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Genetic Predisposition to Diseas | 2012 |
1 trial available for alanine and Diabetic Nephropathies
| Article | Year |
|---|---|
Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications G
Topics: Alanine; Albuminuria; Amino Acid Substitution; Diabetic Nephropathies; Diabetic Retinopathy; Disease | 2008 |
13 other studies available for alanine and Diabetic Nephropathies
| Article | Year |
|---|---|
Development and validation of an LC-MS/MS method for simultaneous determination of remdesivir and its hydrolyzed metabolite and nucleoside, and its application in a pharmacokinetic study of normal and diabetic nephropathy mice.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Chromatography, Liquid; COVID-19 Drug T | 2022 |
Hyperpolarized [1-
Topics: Alanine; Animals; Biomarkers; Diabetic Nephropathies; Fibrosis; Kidney; Rats | 2020 |
Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.
Topics: Alanine; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2 | 2019 |
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Alanine; Angiotensin-Converting Enzyme Inhibitors; Biomarkers | 2013 |
High altitude may alter oxygen availability and renal metabolism in diabetics as measured by hyperpolarized [1-(13)C]pyruvate magnetic resonance imaging.
Topics: Alanine; Altitude; Altitude Sickness; Animals; Atmospheric Pressure; Bicarbonates; Blood Glucose; Di | 2014 |
Peroxisome proliferator activated receptor γ2 gene Pro12Ala gene polymorphism in type 2 diabetes and its relationship with diabetic nephropathy.
Topics: Aged; Aged, 80 and over; Alanine; Amino Acid Substitution; Case-Control Studies; Diabetes Mellitus, | 2014 |
The manganese superoxide dismutase Val16Ala polymorphism is associated with decreased risk of diabetic nephropathy in Chinese patients with type 2 diabetes.
Topics: Aged; Alanine; Alleles; Asian People; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2009 |
Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.
Topics: Alanine; Amino Acid Substitution; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2002 |
[Association of the renin-angiotensin system gene polymorphism with nephropathy in type II diabetes].
Topics: Adult; Alanine; Alleles; Angiotensinogen; Case-Control Studies; Cysteine; Diabetes Mellitus, Type 2; | 2002 |
The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes.
Topics: Aged; Alanine; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Gene | 2003 |
A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy.
Topics: Adult; Age of Onset; Alanine; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fem | 2007 |
Urinary biotinidase and alanine excretion in patients with insulin-dependent diabetes mellitus.
Topics: Acetylglucosaminidase; Adolescent; Adult; Alanine; Albuminuria; Amidohydrolases; Biotinidase; Case-C | 1997 |
Hypoglycemia in compensated chronic renal insufficiency. Substrate limitation of gluconeogenesis.
Topics: Alanine; Carbon Radioisotopes; Diabetic Nephropathies; Female; Fluorometry; Glucagon; Gluconeogenesi | 1974 |